Glenmark Prescribed drugs: US prospects, new medicine make Glenmark look higher

ET Intelligence Group: The inventory of Glenmark Prescribed drugs has proven marginal enchancment of two% in a month, amid greater market volatility, in contrast with a 7% loss incurred within the prior three months. The optimistic sentiment follows expectations of a powerful development trajectory in FY26 led by the US market and its respiratory and injectable portfolio. It has launched key medicine, expanded its world footprint, and superior its oncology pipeline. Analysts have revised the goal worth upwards by over 10%.

Glenmark’s advertising and marketing portfolio as of December 2024 had 201 generic merchandise authorised for distribution within the US. The corporate has 51 functions pending at numerous phases within the approval course of. The corporate acknowledged that its subsidiary, Ichnos Glenmark Innovation (IGI), has a strong pipeline of oncology molecules. Two of those molecules have acquired orphan drug designation from the USFDA. The designation offers incentives like market exclusivity and payment waivers as it’s assigned to medicines developed for uncommon ailments.

In January 2024, the corporate obtained an unique licence for Envafolimab, a most cancers drug. Glenmark plans to file for regulatory approval in over 20 markets with industrial launches anticipated from FY26. In an analyst convention name, the corporate acknowledged that $600 million-$700 million of franchise can be coming to market in FY27. As well as, it has three sole 180-day exclusivities developing in FY27 and FY28, which can be one other $800 million market. The corporate has additionally acquired approval from the Medicines and Healthcare Merchandise Regulatory Company (MHRA) to market WINLEVI in the UK. It’s awaiting approval in its different licensed markets and plans to launch it in FY26.

As of December 2024, Glenmark has submitted advertising and marketing functions for RYALTRIS, a nasal spray for allergy symptoms and runny nostril, in additional than 90 nations, and the product has been commercialised in 43 markets. It expects that this drug would obtain $200-$300 million of peak gross sales over time.

ISB 2001, a trispecific antibody, which goals to deal with a number of myeloma, a kind of blood most cancers, might come up as one other main alternative for Glenmark. “We assume there’s a excessive chance of ISB 2001 securing an out-licensing deal primarily based on its knowledge and rising market optimism for tri-specific antibodies,” acknowledged HSBC International Analysis in a report citing potential gross sales price upwards of $500 million.